The world's first drug opens a new chapter in VMS treatment
2024-06-05
On June 3rd, the Boao Lecheng International Medical Tourism Pilot Zone in Hainan (referred to as the "Lecheng Pilot Zone") and Ansteel China jointly announced that the non hormone, selective neurokinin-3 (NK3) receptor antagonist drug Fezolinentant, pioneered by Ansteel in the world, for the treatment of moderate to severe vasoconstriction symptoms related to menopause, has been officially approved to land in Boao Lecheng. The accessibility of this innovative drug is expected to bring a new non hormonal treatment option for domestic menopausal related hot flashes and night sweats patients. "After more than 20 years of unremitting efforts, the Chinese public's attention to menopausal management has significantly increased, and more and more menopausal women hope to have a better quality of life." Ms. Zhao Ping, President of Ansteel China, stated that "Menopausal syndrome, including night sweats and hot flashes, has brought many troubles to women's bodies and lives. Currently, hormone therapy is the only treatment method that can help patients solve all menopausal related problems. However, due to the limitations of the applicable population and potential safety issues, the use rate of hormone therapy is still very low. Many menopausal women have not received the best treatment. Ansteel is committed to accelerating the introduction of global innovative achievements in China and exploring innovative models to achieve early access to innovative drugs. The pilot trial of Fezolinentant in the Lecheng pilot area will allow Chinese women to use non hormone therapy drugs with new mechanisms of action in sync with women in Europe and America." Improve the problem of night sweating and hot flashes in menopausal women, and regain a better life As an open and innovative pharmaceutical industry platform, the development of Lecheng cannot do without the support of our partners. Through the collaboration and promotion of various parties, Lecheng is able to gather more and more high-quality medical resources, continuously improve the level and quality of medical services, and provide cutting-edge and leading solutions for people's health. Anstelai and Lecheng have established long-term friendly cooperation in innovative drug trials and have achieved a series of results. I hope to continue to engage in extensive and in-depth cooperation with advanced international pharmaceutical and equipment enterprises such as Anstela in the future, promote the accelerated introduction of more innovative drugs and treatment plans, and further enhance the accessibility of innovative drugs to domestic patients Jia Ning, Secretary of the Party Committee and Director of the Boao Lecheng International Medical Tourism Pilot Zone Management Bureau, stated. Vascular vasoconstriction syndrome (VMS), also known as hot flashes and/or night sweats, is one of the most common complaints among postmenopausal women. Hot flashes suddenly occur from the head, neck, chest, and upper back, with rosy skin, elevated temperature, and a sensation of warmth throughout the body. These symptoms usually last for 1-5 minutes, followed by symptoms such as chills, chills, anxiety, and even occasional palpitations. Patients with moderate to severe vasoconstriction symptoms may also experience sleep problems, fatigue, anxiety, and depression, which may also affect their daily activities and work abilities. A study on female reproductive aging in China found that up to 80% of perimenopausal women are troubled by this problem, with over 50% experiencing moderate to severe symptoms, which is consistent with data from European and American countries. The median duration of VMS among women in China is 4.5 years. VMS related to menopause can have potential negative impacts on women's health, quality of life, and socio-economic outcomes. Symptoms of vasodilation and contraction pose serious challenges to the daily life and work of perimenopausal women, but traditional treatment methods still have limitations. The most commonly used treatment method for relieving menopausal related VMS is menopausal hormone therapy. However, there are many contraindications to the use of menopausal hormone therapy, which has a therapeutic window. Studies have proved that it may also increase the risk of breast cancer, cardiovascular disease and thromboembolism. Femolinetant, pioneered by Anstella, is the world's first non hormonal, selective neurokinin-3 (NK3) receptor antagonist approved for the treatment of menopausal related vasoconstriction symptoms (VMS). It can block the binding of neurokinin-B (NKB) to kisspeptin/neurokinin-B/dynorphin (KNDy) meridians, thereby regulating neuronal activity in the thermoregulatory center and reducing the frequency and severity of menopausal related VMS. The efficacy and safety of this product have been determined through three global Phase III clinical studies, all of which have achieved all major efficacy endpoints. At the 4th and 12th week after treatment, the frequency and severity of moderate to severe VMS in the Veoza 45 mg group were significantly lower than those in the placebo group compared to baseline, and it was confirmed that the overall safety of Veoza 45 mg treatment was good after 52 weeks. Previously, Fezolinentant had been approved by the United States and Europe in May and December 2023 for the treatment of moderate to severe vasoconstriction symptoms related to menopause. It is reported that Lecheng Pilot Zone was established on February 28, 2013 with the approval of the State Council, and enjoys special preferential policies granted by the state, such as licensed medical treatment, licensed operation, licensed research, and licensed international exchange. It is the only "medical special zone" in the country. In recent years, driven by the advantages of the Hainan Free Trade Port and the "first in, first out" policy, the Lecheng Pilot Zone has basically achieved the "three synchronization" of medical technology, equipment, and drugs with international advanced levels, becoming the main channel for international innovative pharmaceutical devices to enter the Chinese market first. In the past few years, Anstailai Company has continuously deepened its cooperation with Lecheng Management Bureau, actively joined hands to introduce international innovative drugs, and worked together to benefit Chinese patients. (Lai Xin She)
Edit:GuoGuo Responsible editor:FangZhiYou
Source:gmw.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email:lwxsd@liaowanghn.com